Paid Clinical Trials in Sydney Australia

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Sydney

Top of Directory » All Locations » Australia » Sydney


  • CoreValve® System Australia/New Zealand Clinical Study

    Condition:   Aortic Valve Stenosis
    Intervention:   Device: Medtronic CoreValve® System
    Sponsors:   Medtronic Heart Valves;   Medtronic Vascular;   Medtronic Australasia
    Recruiting - verified November 2009

  • Nexus Compliance Study

    Condition:   Obstructive Sleep Apnea
    Interventions:   Device: Nexus CPAP;   Device: CPAP
    Sponsor:   ResMed
    Not yet recruiting - verified November 2009

  • Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

    Condition:   Retinal Vein Occlusion
    Interventions:   Drug: VEGF Trap-Eye (BAY86-5321);   Other: Sham treatment
    Sponsors:   Bayer;   Regeneron Pharmaceuticals
    Recruiting - verified November 2009

  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

    Condition:   Melanoma
    Interventions:   Drug: Bosentan;   Drug: Placebo
    Sponsor:   Actelion
    Completed - verified November 2009

  • A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

    Condition:   Neoplasms
    Interventions:   Drug: R1507;   Drug: RAD001
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

    Condition:   Influenza
    Interventions:   Drug: Oseltamivir Phosphate;   Drug: ADS-8902
    Sponsor:   Adamas Pharmaceuticals, Inc.
    Recruiting - verified September 2009

  • TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

    Condition:   Hepatitis C
    Interventions:   Drug: TMC435 placebo /Peg IFNa2A/Ribavirin;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin TMC435 placebo;   Drug: TMC435 /Peg IFNa2A/Ribavirin
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Recruiting - verified November 2009

  • A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

    Condition:   Malignant Melanoma
    Intervention:   Drug: RO5185426
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: erlotinib [Tarceva];   Drug: gemcitabine;   Drug: gemcitabine
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

    Condition:   Bronchiectasis
    Interventions:   Drug: Cipro (Ciprofloxacin, BAYQ3939);   Drug: Placebo
    Sponsors:   Bayer;   Novartis
    Recruiting - verified November 2009

  • Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease

    Condition:   Peripheral Arterial Disease
    Intervention:   Procedure: Ankle-brachial index (ABI) Screening Test
    Sponsors:   AstraZeneca;   Pretium Pty Ltd
    Completed - verified November 2009

  • A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera (Rituximab) in Patients With Follicular Lymphoma

    Condition:   Follicular Lymphoma
    Interventions:   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: abiraterone acetate plus prednisone/prednisolone;   Drug: placebo plus prednisone/prednisolone
    Sponsor:   Cougar Biotechnology, Inc.
    Recruiting - verified November 2009

  • TMC435-TiDP16-C205: A Phase II Study of TMC435 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

    Condition:   Hepatitis C
    Interventions:   Drug: TMC435 Ribavirin;   Drug: Ribavirin PegIFNalpha-2a;   Drug: TMC435 TMC435 Placebo;   Drug: TMC435 Ribavirin;   Drug: PegIFNalpha-2a;   Drug: Ribavirin PegIFNalpha-2a;   Drug: PegIFNalpha-2a;   Drug: PegIFNalpha-2a;   Drug: TMC435 TMC435 Placebo;   Drug: TMC435 Placebo Ribavirin
    Sponsor:   Tibotec Pharmaceuticals, Ireland
    Recruiting - verified November 2009

  • Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

    Conditions:   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: bendamustine and rituximab;   Drug: R-CVP or R-CHOP
    Sponsor:   Cephalon
    Recruiting - verified November 2009

  • A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma

    Condition:   Multiple Myeloma
    Intervention:   Drug: bortezomib; doxorubicin; dexamethasone
    Sponsor:   Janssen-Cilag Pty Ltd
    Recruiting - verified November 2009

  • BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

    Condition:   Hypertension, Pulmonary
    Intervention:   Drug: Riociguat (BAY63-2521)
    Sponsor:   Bayer
    Enrolling by invitation - verified November 2009

  • A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma

    Condition:   Non-Hodgkin's Lymphoma
    Interventions:   Drug: RO5072759;   Drug: RO5072759;   Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone);   Drug: FC(fludarabine,cyclophosphamide)
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged Between >= 6 Months to < 18 Years

    Condition:   Influenza
    Intervention:   Biological: CSL Limited Influenza Virus Vaccine
    Sponsor:   CSL Limited
    Active, not recruiting - verified November 2009

  • Safety of Gadovist in Renally Impaired Patients

    Conditions:   Fibrosis;   Renal Impairment
    Intervention:   Drug: Gadovist (Gadobutrol, BAY86-4875)
    Sponsor:   Bayer
    Recruiting - verified November 2009

  • A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

    Condition:   Pulmonary Hypertension
    Interventions:   Drug: Riociguat (BAY63-2521);   Drug: Riociguat (BAY63-2521);   Drug: Placebo
    Sponsor:   Bayer
    Recruiting - verified November 2009

  • A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: bevacizumab [Avastin];   Drug: bevacizumab [Avastin];   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Active, not recruiting - verified November 2009

  • A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor.

    Condition:   Resected Stage III Melanoma With Macroscopic Involvement
    Interventions:   Drug: GSK 2132231A;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting - verified July 2009

  • Efficacy and Safety of RAD001 in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)

    Condition:   Tuberous Sclerosis
    Interventions:   Drug: RAD001 (Everolimus);   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

    Condition:   Leukemia
    Intervention:   Drug: Midostaurin
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache

    Conditions:   Oral Contraceptive;   Headache;   Pelvic Pain
    Interventions:   Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID);   Drug: Encapsulated Microgynon + Placebo
    Sponsor:   Bayer
    Recruiting - verified November 2009

  • Safety and Efficacy of Positron Emission Tomography Imaging With BAY 94-9172 (ZK 6013443)

    Conditions:   Alzheimer Disease;   Amyloid Beta-Protein
    Intervention:   Drug: BAY94-9172 (ZK 6013443)
    Sponsor:   Bayer
    Recruiting - verified November 2009

  • A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer

    Condition:   Advanced/Metastatic Non-Small Cell Lung Cancer
    Interventions:   Drug: Ixabepilone + Carboplatin;   Drug: Paclitaxel + Carboplatin
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified July 2009

  • FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

    Conditions:   Colorectal Cancer;   Colorectal Carcinoma;   Liver Metastases
    Interventions:   Drug: Systemic chemotherapy (FOLFOX);   Device: SIR-Spheres yttrium-90 microspheres;   Drug: Systemic chemotherapy (FOLFOX)
    Sponsor:   Sirtex Medical
    Recruiting - verified November 2009

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL)

    Condition:   HIV Infection
    Interventions:   Drug: elvitegravir;   Drug: Raltegravir
    Sponsor:   Gilead Sciences
    Recruiting - verified October 2009

  • A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month Old Infants

    Conditions:   Respiratory Syncytial Virus (RSV);   Parainfluenza Virus Type 3 (PIV3)
    Interventions:   Biological: MEDI-534;   Biological: MEDI-534;   Biological: MEDI-534;   Biological: MEDI-534;   Biological: MEDI-534;   Biological: Placebo
    Sponsor:   MedImmune LLC
    Recruiting - verified October 2009

  • A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

    Condition:   Pancreatic Cancer
    Interventions:   Drug: erlotinib [Tarceva];   Drug: erlotinib [Tarceva];   Drug: gemcitabine
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.

    Condition:   Sarcoma
    Intervention:   Drug: R1507
    Sponsors:   Hoffmann-La Roche;   Sarcoma Alliance for Research through Collaboration
    Recruiting - verified November 2009

  • Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) (VIEW 2)

    Condition:   Macular Degeneration
    Interventions:   Drug: VEGF Trap-Eye;   Drug: VEGF Trap-Eye;   Drug: VEGF Trap-Eye;   Drug: Ranibizumab
    Sponsor:   Bayer
    Active, not recruiting - verified November 2009

  • Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers

    Conditions:   Melanoma;   Breast Cancer;   Prostate Cancer
    Intervention:   Drug: CVA21
    Sponsor:   Viralytics
    Recruiting - verified November 2009

  • Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors

    Condition:   Advanced Solid Tumors
    Intervention:   Drug: BMS-777607
    Sponsor:   Bristol-Myers Squibb
    Completed - verified August 2009

  • Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

    Condition:   Inflammatory Breast Cancer
    Interventions:   Drug: lapatinib (Tykerb);   Drug: pazopanib (GW786034);   Drug: Pazopanib
    Sponsor:   GlaxoSmithKline
    Recruiting - verified October 2009

  • BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.

    Condition:   Breast Cancer
    Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard adjuvant chemotherapy
    Sponsor:   Hoffmann-La Roche
    Active, not recruiting - verified November 2009

  • Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus)

    Conditions:   Metastatic Soft-Tissue Sarcomas;   Metastatic Bone Sarcomas
    Interventions:   Drug: ridaforolimus;   Drug: Placebo
    Sponsors:   Ariad Pharmaceuticals;   Merck
    Recruiting - verified November 2009

  • A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: erlotinib [Tarceva];   Drug: Gemcitabine
    Sponsor:   Hoffmann-La Roche
    Completed - verified November 2009

  • The PRIMO Study-Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Chronic Kidney Disease Stage 3/4

    Conditions:   Chronic Kidney Disease;   Left Ventricular Hypertrophy
    Interventions:   Drug: paricalcitol;   Drug: placebo
    Sponsors:   Abbott;   Massachusetts General Hospital;   Harvard University
    Active, not recruiting - verified October 2009

  • ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

    Condition:   Breast Cancer
    Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

    Condition:   Idiopathic Thrombocytopenic Purpura
    Intervention:   Drug: rituximab [MabThera/Rituxan]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.

    Condition:   Breast Cancer
    Interventions:   Drug: bevacizumab [Avastin];   Drug: Taxane-based chemotherapy
    Sponsor:   Hoffmann-La Roche
    Active, not recruiting - verified November 2009

  • A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: bevacizumab [Avastin];   Drug: Platinum-based chemotherapy
    Sponsor:   Hoffmann-La Roche
    Active, not recruiting - verified November 2009

  • Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Deep-Vein Thrombosis Without Symptomatic Pulmonary Embolism: Einstein-DVT Evaluation

    Conditions:   Venous Thrombosis;   Deep Vein Thrombosis
    Interventions:   Drug: Xarelto (Rivaroxaban, BAY59-7939);   Drug: Enoxaparin followed by VKA
    Sponsors:   Bayer;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Active, not recruiting - verified October 2009

  • A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan];   Drug: rituximab [MabThera/Rituxan]
    Sponsor:   Hoffmann-La Roche
    Active, not recruiting - verified November 2009

  • Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

    Conditions:   Atrial Fibrillation;   Atrial Flutter
    Interventions:   Drug: warfarin;   Drug: apixaban
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified October 2009

  • REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

    Condition:   Multiple Sclerosis
    Interventions:   Drug: Rebif New Formulation (RNF);   Drug: Rebif New Formulation (RNF);   Drug: Placebo
    Sponsor:   EMD Serono
    Active, not recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials